All In Biotech

Drug Trial Radar · NCT06602258

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

105

Actual

Start

Sep 30, 2024

Primary completion

Dec 3, 2026

Study completion Aug 18, 2027

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer's disease (AD).

Conditions

  • Alzheimer's Disease

Interventions

  • E2814Drug

    E2814 IV infusion.

  • LecanemabDrug

    Lecanemab SC injection.

  • PlaceboDrug

    Placebo IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in CSF MTBR-tau-243 at 6 MonthsTime frame: Baseline at 6 months

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Banner Sun Health Research

    Phoenix, Arizona

  • Yale University School of Medicine

    New Haven, Connecticut

  • Bradenton Research Center

    Bradenton, Florida

  • K2 Medical Research

    Clermont, Florida

  • Advanced Clinical Research Network

    Miami, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Alzheimer's Research and Treatment Center-Stuart

    Stuart, Florida

  • Axiom Brain Health

    Tampa, Florida

  • Charter Research

    The Villages, Florida

  • Alzheimer's Research and Treatment Center

    Wellington, Florida

  • Columbus Memory Center, PC

    Columbus, Georgia

  • Hattiesburg Clinic

    Hattiesburg, Mississippi

  • Washington University School of Medicine

    St Louis, Missouri

  • Abington Neurological Associates LTD

    Abington, Pennsylvania

  • Neurology Clinic, P.C.

    Cordova, Tennessee

  • Kerwin Memory Center

    Dallas, Texas

  • National Clinical Research-Richmond, Inc

    Richmond, Virginia

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Yamagata Tokushukai Hospital

    Yamagata, Japan

  • National Center for Geriatrics and Gerontology

    Ōbu, Aichi-ken, Japan

  • National Hospital Organization Hiroshima-Nishi Medical Center

    Ōtake, Hiroshima, Japan

  • Keimei Memorial Hospital

    Honjō, Miyazaki, Japan

  • Rijikai Medical Corporation Katayama Medical Clinic

    Kurashiki, Okayama-ken, Japan

  • Tokyo Medical University Hospital

    Shinjuku, Tokyo, Japan

  • Keio University Hospital

    Shinjuku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.